Literature DB >> 19630746

Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences.

Kristin E Bogle1, Bradley H Smith.   

Abstract

Methylphenidate hydrochloride (MPH) is one of the most widely available prescription stimulants. In response to an increase in stimulant treatment for Attention-Deficit/Hyperactivity Disorder, the prescription and production rates of MPH have increased dramatically in the past two decades. Given that college students and adolescents might be attracted to MPH for its attention-focusing, weight loss, or euphoric effects, there is concern that the rise in therapeutic use of MPH might also coincide with a rise in illicit (non-medical) use. After a dramatic increase in the 1990s, recent large-scale surveys of high-school students suggest that rates of illicit MPH use are either holding steady, or even decreasing in this population. Across studies, annual usage rates for secondary school students are below 5%, and lifetime usage rates remain below 7%. Among college students, self-reported rates range from 1.5% to 31% among the various surveys, with the most nationally representative study estimating annual illicit MPH usage at about 4%. Although more research is needed to corroborate findings, this review was able to begin developing a profile of individuals who might be more likely to illicitly use MPH. Among college students, available evidence suggests illicit MPH users were more likely to be white, male, affiliated with a formally organized fraternity, and more likely to use other illicit and illegal substances. The majority of college students reported that the primary reason for use was to improve academic performance. Future studies should provide more information on the motivations and subtypes of illicit MPH, especially repeated users and those diagnosed with ADHD. Research on prevention of illicit MPH or other stimulants used to treat ADHD would make major contributions to the literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630746     DOI: 10.2174/1874473710902020157

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  30 in total

1.  Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate.

Authors:  Nicholas King; Samuel Floren; Natasha Kharas; Ming Thomas; Nachum Dafny
Journal:  Pharmacol Biochem Behav       Date:  2019-06-19       Impact factor: 3.533

2.  Oral methylphenidate establishes a conditioned place preference in rats.

Authors:  Thomas E Wooters; Matthew T Walton; Michael T Bardo
Journal:  Neurosci Lett       Date:  2010-10-23       Impact factor: 3.046

3.  Chronic oral methylphenidate treatment increases microglial activation in rats.

Authors:  Emily Carias; John Hamilton; Lisa S Robison; Foteini Delis; Rina Eiden; Teresa Quattrin; Michael Hadjiargyrou; David Komatsu; Panayotis K Thanos
Journal:  J Neural Transm (Vienna)       Date:  2018-09-20       Impact factor: 3.575

Review 4.  Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Authors:  Jochen Antel; Özgür Albayrak; Gerd Heusch; Tobias Banaschewski; Johannes Hebebrand
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-23       Impact factor: 5.270

5.  Caudate neuronal recording in freely behaving animals following acute and chronic dose response methylphenidate exposure.

Authors:  Catherine M Claussen; Nachum Dafny
Journal:  Pharmacol Biochem Behav       Date:  2015-06-20       Impact factor: 3.533

6.  Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum.

Authors:  Vincent Van Waes; Joel Beverley; Michela Marinelli; Heinz Steiner
Journal:  Eur J Neurosci       Date:  2010-08       Impact factor: 3.386

7.  Sharing and borrowing prescription medication: a survey of Irish college students.

Authors:  E Goulding; M Murphy; Z Di Blasi
Journal:  Ir J Med Sci       Date:  2011-02-18       Impact factor: 1.568

8.  Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats.

Authors:  Lisa S Robison; Mala Ananth; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos
Journal:  J Neural Transm (Vienna)       Date:  2017-01-23       Impact factor: 3.575

9.  A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.

Authors:  Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow
Journal:  Pharmacol Biochem Behav       Date:  2015-01-29       Impact factor: 3.533

10.  Effects of acute doses of methylphenidate on inflammation and oxidative stress in isolated hippocampus and cerebral cortex of adult rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Behnaz Shabab; Sulail Fatima
Journal:  J Neural Transm (Vienna)       Date:  2016-09-28       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.